Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559254 | 0.91 | PRKDC (0.42) | PIK3CAGRIA1MTORPDPK1MAP3K11 | |
| SCHEMBL4557228 | 0.82 | PIK3CA (0.47) | PIK3CAGRIA1MTORPDPK1MAP3K11 | |
| SCHEMBL4559248 | 0.73 | PIK3CA (0.43) | PIK3CAGRIA1MTORPDPK1MAP3K11 | |
| SCHEMBL4557226 | 0.73 | JAK2 (0.42) | PIK3CAMTORPDPK1KDM4EALDH1A1 | |
| SCHEMBL18108512 | 0.72 | PIK3CA (0.63) | PIK3CAMTORMAP3K11QPCTAKT1 | |
| SCHEMBL2726275 | 0.68 | MTOR (0.51) | PIK3CAGRIA1MTORMAP3K11PIK3CG | |
| SCHEMBL719270 | 0.68 | ROCK2 (0.43) | PIK3CAMTORHTTPRKDCNOS1 | |
| SCHEMBL4557224 | 0.67 | JAK2 (0.43) | PIK3CAMTORPDPK1AKT1KDM4E | |
| SCHEMBL13650807 | 0.67 | NOS1 (0.60) | PIK3CAPOLBHTTNOS1KDM4E | |
| SCHEMBL8826341 | 0.67 | IKBKB (0.52) | PIK3CAMTORPDPK1PIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20120253039-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-7582648-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080312438-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-7452879-B2 | N4-(1-tert-Butoxycarbonylazetidin-3-yl)-5-fluoro-N2-(4-morpholinophenyl)-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for IgE (\"Fc epsilon RI\") and IgG (\"Fc gamma RI\") antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070167439-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20050234049-A1 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | MIDCAP FINANCIAL TRUST | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259826-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | PIK3CA 3886/4885GRIA1 2168/4885MTOR 2694/4885 |
| US-20120253039-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | PIK3CA 3886/4885GRIA1 2168/4885MTOR 2694/4885 |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | PIK3CA 3886/4885GRIA1 2168/4885MTOR 2694/4885 |
| US-20070167439-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | PIK3CA 3732/4885GRIA1 2356/4885MTOR 3056/4885 |
| US-20080312438-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | PIK3CA 3732/4885GRIA1 2356/4885MTOR 3056/4885 |
| US-20050234049-A1 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | SSB, HRH4, TLR7 | PIK3CA 3728/4885GRIA1 1682/4885MTOR 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.